AARP applauds the FDA’s approval of the first biosimilar prescription drug product in the U.S. It is a welcome step toward a workable approval process that will provide consumers with much-needed access to safe, effective biosimilar drugs, as envisioned by the Biologics Price Competition and Innovation Act in the Affordable Care Act.
My mother had a cleft palate. It was fixed when she was three years-old, and you could never tell anything was wrong by looking at her, but it left her with two impediments: her speech and her mother.
Search AARP Blogs